{
    "clinical_study": {
        "@rank": "97408", 
        "arm_group": {
            "arm_group_label": "CPI-613 Alone", 
            "arm_group_type": "Experimental", 
            "description": "This arm is for patients that have failed, or are not eligible for, all available therapies. CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration.  CPI-613 is to be infused intravenously (IV) via a central venous catheter.  CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr."
        }, 
        "brief_summary": {
            "textblock": "This Phase II study is conducted to assess the safety and efficacy of CPI-613 in patients\n      with advanced and/or metastatic solid tumors for whom there there is no available therapy to\n      provide clinical benefit or for those who have refused further standard therapy.  The\n      primary outcome measure is Overall Survival (OS).  The secondary outcome measures are:\n      Response Rate (RR), Progression-Free Survival (PFS), and safety."
        }, 
        "brief_title": "Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Solid Tumor Cancer", 
            "Metastatic Solid Tumor Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have advanced and/or metastatic, histologically or cytologically\n             documented solid tumors, for whom there is no available therapy shown to provide\n             clinical benefit or for those who have refused further standard therapy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status being 0-2\n\n          -  Expected survival >3 months\n\n          -  18 years of age or older of both genders\n\n          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not\n             surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine\n             device [IUD], oral contraceptive or double barrier device) during the study, and must\n             have a negative serum or urine pregnancy test within 1 week prior to treatment\n             initiation. (Note: Pregnant patients are excluded because the effects of CPI-613 on a\n             fetus are unknown.)\n\n          -  Fertile men must practice effective contraceptive methods during the study, unless\n             documentation of infertility exists\n\n          -  Mentally competent, with an ability to understand and willingness to sign the\n             informed consent form\n\n          -  No radiotherapy, treatment with cytotoxic agents (except CPI-613), or treatment with\n             biologic agents within 3 weeks prior to treatment with CPI-613. At least 2 weeks must\n             have elapsed from any prior surgery or hormonal therapy. Patients must have fully\n             recovered from the acute toxicities of any prior treatment with any anti-cancer\n             drugs, radiotherapy or other anti-cancer modalities (returned to baseline status as\n             noted before most recent treatment). Patients with persisting, stable chronic\n             toxicities from prior treatment \u2264Grade 1 are eligible, but must be documented as\n             such.\n\n          -  Laboratory values \u22642 weeks must be:\n\n               -  Adequate hematologic (white blood cell [WBC] \u22653500 cells/mm3 or \u22653.5 bil/L;\n                  platelet count \u2265150,000 cells/mm3 or \u2265150 bil/L; absolute neutrophil count [ANC]\n                  \u22651500 cells/mm3 or \u22651.5 bil/L; and hemoglobin (Hgb) \u22659 g/dL or \u226590 g/L).\n\n               -  Adequate hepatic function (aspartate aminotransferase [AST/SGOT] \u22643x upper\n                  normal limit [UNL], alanine aminotransferase [ALT/SGPT] \u22643x UNL (\u22645x UNL if\n                  liver metastases present), bilirubin \u22641.5x UNL).\n\n               -  Adequate renal function (serum creatinine \u22642.0 mg/dL or 177 \u03bcmol/L, and blood\n                  urea nitrogen [BUN] \u226425 mg/dL).\n\n               -  Adequate coagulation (\"International Normalized Ratio or INR must be \u22641.5\")\n\n        Exclusion Criteria:\n\n          -  Serious medical illness, such as significant cardiac disease (e.g. symptomatic\n             congestive heart failure, unstable angina pectoris, myocardial infarction within the\n             past 6 months, uncontrolled cardiac arrhythmia, or New York Heart Association Class\n             III or IV), or severe debilitating pulmonary disease, that would potentially increase\n             patients' risk for toxicity.\n\n          -  Any active uncontrolled bleeding or patients with a bleeding diathesis (e.g., active\n             peptic ulcer disease)\n\n          -  Patients with active central nervous system (CNS) or epidural tumor\n\n          -  Pregnant women, or women of child-bearing potential not using reliable means of\n             contraception (because the teratogenic potential of CPI-613 is unknown)\n\n          -  Lactating females (Note: Lactating females are excluded because the effects of\n             CPI-613 on a nursing child are unknown)\n\n          -  Fertile men unwilling to practice contraceptive methods during the study period\n\n          -  Life expectancy less than 3 months\n\n          -  Unwilling or unable to follow protocol requirements\n\n          -  Dyspnea with minimal to moderate exertion, or patients with pleural, pericardial, or\n             peritoneal effusions\n\n          -  Active heart disease including but not limited to symptomatic congestive heart\n             failure, symptomatic coronary artery disease, symptomatic angina pectoris,\n             symptomatic myocardial infarction, arrhythmias requiring medication, or symptomatic\n             congestive heart failure.\n\n          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated exhibition of a QTc\n             interval >470 ms.); a history of additional risk factors for torsade de pointes\n             (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n\n          -  Requirement for immediate palliative treatment of any kind including surgery\n\n          -  Any condition or abnormality which may, in the opinion of the investigator,\n             compromise the safety of patients\n\n          -  Albumin <2.5 g/dL or <25 g/L\n\n          -  Evidence of active infection, or serious infection, with the past month\n\n          -  Patients with known HIV infection. (Note: Patients with known HIV infection are\n             excluded because patients with an immune deficiency are at increased risk of lethal\n             infections when treated with marrow-suppressive therapy, and because there may be\n             unknown or dangerous drug interactions between CPI-613 and anti-retroviral agents\n             used to treat HIV infections.)\n\n          -  Patients receiving any other standard or investigational treatment for their cancer,\n             or any other investigational agent for any indication within the past 3 weeks prior\n             to initiation of CPI-613 treatment.\n\n          -  Patients who have received immunotherapy of any type within the past 4 weeks prior to\n             initiation of CPI-613 treatment\n\n          -  Patients that have received a chemotherapy regimen with stem cell support in the\n             previous 6 months\n\n          -  Troponin I above institution limit of normal"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832857", 
            "org_study_id": "CL-CPI-613-023"
        }, 
        "intervention": {
            "arm_group_label": "CPI-613 Alone", 
            "description": "CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.", 
            "intervention_name": "CPI-613", 
            "intervention_type": "Drug", 
            "other_name": [
                "6,8-bis-benzylsulfanyloctanoic acid", 
                "6,8-bis(benzylthio)octanoic acid", 
                "6,8-bis-benzylsulfonyloctanoic acid", 
                "Bylantra (tentative)"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "metastatic", 
            "advanced", 
            "solid tumor", 
            "cancer", 
            "colon cancer", 
            "hepatocellular carcinoma", 
            "breast cancer", 
            "lung cancer", 
            "gastric cancer", 
            "esophageal cancer"
        ], 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "contact": {
                "email": "retter@eastchestercenter.com", 
                "last_name": "Avi S Retter, M.D.", 
                "phone": "718-732-4000"
            }, 
            "contact_backup": {
                "email": "karen@eastchestercenter.com", 
                "last_name": "Karen Hoffman, M.D.", 
                "phone": "(718) 732-4029"
            }, 
            "facility": {
                "address": {
                    "city": "Bronx", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10469"
                }, 
                "name": "Eastchester Center for Cancer Care"
            }, 
            "investigator": [
                {
                    "last_name": "Avi S Retter, M.D.", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Karen Hoffman, M.D.", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Phase 2 Trial to Evaluate the Safety, Tolerability and Efficacy of CPI-613 in Cancer Patients", 
        "overall_contact": {
            "email": "king@cornerstonepharma.com", 
            "last_name": "King C Lee, Ph.D.", 
            "phone": "203-239-2021"
        }, 
        "overall_contact_backup": {
            "email": "claudia@cornerstonepharma.com", 
            "last_name": "Claudia B Maturo, M.Sc.", 
            "phone": "631-444-6868"
        }, 
        "overall_official": {
            "affiliation": "Cornerstone Pharmaceuticals, Inc.", 
            "last_name": "King C Lee, Ph.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board (WIRB)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Survival (OS)", 
            "safety_issue": "No", 
            "time_frame": "Monitored until participants pass away, for an expected average of 6 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832857"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Monitored during treatment with CPI-613 and until participants passed away, which will be an expected average of 6 months."
            }, 
            {
                "description": "Safety assessment will be based on clinical signs, vital signs, blood work, adverse events (AEs), serious adverse events (SAEs), etc.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Monitored just before study treatment, and during study treatment at the end of every 4-week treatment cycle, for an expected average of 20 weeks."
            }, 
            {
                "measure": "Response Rate", 
                "safety_issue": "No", 
                "time_frame": "Monitored at the end of every 4-week treatment cycle during treatment with CPI-613, for an expected average of 20 weeks."
            }
        ], 
        "source": "Cornerstone Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cornerstone Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}